UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________

FORM 10-Q

________________________________________________________


			☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~September 30~~March 31, ~~2025~~ 2026


			☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No.: 001-36534

________________________________________________________

IRADIMED CORPORATION

(Exact name of Registrant as specified in its charter)


Delaware			73-1408526
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification Number)

12705 Ingenuity Drive Orlando, Florida			32826
(Address of principal executive offices)			(Zip Code)


Delaware		73-1408526
(State or other jurisdiction ofincorporation or organization)		(I.R.S. EmployerIdentification Number)

12705 Ingenuity DriveOrlando, Florida		32826
(Address of principal executive offices)		(Zip Code)

(407) 677-8022

(Registrant’s telephone number, including area code)

N/A

(Former Name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

Trading Symbol

Name of each exchange on which registered:

Common stock, par value $0.0001

IRMD

NASDAQ Global Market

Title of each class:		Trading Symbol		Name of each exchange on which registered:
Common stock, par value $0.0001		IRMD		NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had 12,~~721~~783,~~156~~035 shares of common stock, par value $0.0001 per share, outstanding as of ~~October 31~~April 30, ~~2025~~2026.

Table of Contents

IRADIMED CORPORATION

Table of Contents

			Page
					Page
Cautionary Note Regarding Forward-Looking Statements			3		3

Part I			Financial Information		6
Part I	Financial Information		6
			Item 1	Financial Statements	6

				(a) Condensed Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025 (Audited)	6
	Item 1	Financial Statements	6
				(b) Condensed Statements of Operations for the three months ended March 31, 2026 and 2025 (Unaudited)	7

				(c) Condensed Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025 (Unaudited)	8
		(a) Condensed Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 (Audited)	6
				(d) Condensed Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (Unaudited)	9

				(e) Notes to Unaudited Condensed Financial Statements	10
		(b) Condensed Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited)	7
			Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

			Item 3	Quantitative and Qualitative Disclosures About Market Risk	24
		(c) Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2025 and 2024 (Unaudited)	8
			Item 4	Controls and Procedures	24

Part II			Other Information		25
		(d) Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited)	9
			Item 1	Legal Proceedings	25

			Item 1A	Risk Factors	25
		(e) Notes to Unaudited Condensed Financial Statements	10
			Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	25

			Item 3	Default Upon Senior Securities	25
	Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
			Item 4	Mine Safety Disclosures	25

			Item 5	Other Information	25
	Item 3	Quantitative and Qualitative Disclosures About Market Risk	23
			Item 6	Exhibits	26

Signatures					27
	Item 4	Controls and Procedures	24

Part II	Other Information		25

	Item 1	Legal Proceedings	25

	Item 1A	Risk Factors	25

	Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	25

	Item 3	Default Upon Senior Securities	25

	Item 4	Mine Safety Disclosures	25

	Item 5	Other Information	25

	Item 6	Exhibits	26

Signatures			27

Table of Contents

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Quarterly Report on Form 10-Q for the quarter ended ~~September~~March 3031, ~~2025~~ 2026 (this “"Quarterly Report”") that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “"Securities Act”"), and Section 21E of the Securities Exchange Act of 1934, as amended (the “"Exchange Act”"), and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. When used in this Quarterly Report the words “"believe,”" “"anticipate,”" “"expect,”" “"may,”" “"will,”" “"assume,”" “"should,”" “"predict,”" “"could,”" “"would,”" “"intend,”" “"targets,”" “"estimates,”" “"projects,”" “"plans,”" "forecast," "outlook," "guidance," "continue," and “"potential,”" and other similar words and expressions of the future, are intended to identify such forward-looking statements, but other statements not based on historical information may also be considered forward-looking, including statements about the Company’'s future financial and operating results and the Company’'s plans, objectives, and intentions. Forward-looking statements include, among other things, statements about the matters set forth in this Quarterly Report, including those described in the risk factors below. All forward-looking statements are subject to risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from any results, performance, or achievements expressed or implied by such forward-looking statements. These ~~forward-looking statements are subject to known and unknown~~ risks, uncertainties and other factors ~~that could cause the actual results to differ materially from the statements~~include, ~~including,~~ but are not limited to:

● •our ability to receive 510(k) clearance for our products and product candidates, complete inspections conducted by the U.S. Food & Drug Administration (~~the~~ “FDA”) or other regulatory bodies resulting in favorable outcomes, additional actions by or requests from the FDA, including a request to cease domestic distribution of products, or other regulatory bodies and unanticipated costs or delays associated with the resolution of these matters;

● •the timing and likelihood of regulatory approvals or clearances from the FDA or other regulatory bodies and regulatory actions on our product candidates and product marketing activities;

● •unexpected costs, expenses and diversion of management attention resulting from actions or requests posed to us by the FDA or other regulatory bodies;

● •failure to obtain and/or maintain regulatory approvals ~~or clearances~~ and comply with applicable regulations;

● •our primary reliance on a limited number of products;

● •our ability to retain the continued service of our key professionals, including key management, marketing and scientific personnel, and to identify, hire and retain such additional qualified professionals;

● •our expectations regarding the sales and marketing of our products, product candidates and services;

● •our expectations regarding the integrity of our supply chain for our products;

● •the potential for adverse application of environmental, health and safety and other laws and regulations of any jurisdiction on our operations;

● •our expectations for market acceptance of our new products;

● •the potential for our marketed products to be withdrawn due to recalls, patient adverse events or deaths;

● •our ability to successfully prepare, file, prosecute, maintain, defend, including in cases of infringement, and enforce patent claims and other intellectual property rights on our products;

● •our ability to identify and pursue development of additional products;

•the implementation of our business strategies;

•the potential for exposure to product liability claims;

•our financial performance expectations and interpretations thereof by securities analysts and investors;

Table of Contents

●•our ability to compete in the ~~implementation~~development and marketing of our ~~business~~products ~~strategies~~and product candidates with existing companies and new market entrants in our industry;

●•difficulties or delays in the ~~potential~~development, ~~for~~production, ~~exposure~~manufacturing toand ~~product~~marketing ~~liability~~of ~~claims~~new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;

●•changes ~~our~~in ~~financial~~laws ~~performance~~and ~~expectations~~regulations ~~and~~or ~~interpretations~~in ~~thereof~~the byinterpretation ~~securities~~or ~~analysts~~application ~~and~~of ~~investors~~laws or regulations, as well as possible failures to comply with applicable laws or regulations as a result of possible misinterpretations or misapplications;

●•cost-containment ~~our~~efforts ~~ability to compete in the development and marketing~~ of our ~~products~~customers, ~~and~~purchasing ~~product~~groups, ~~candidates~~third-party ~~with~~payers ~~existing companies~~ and ~~new~~governmental ~~market entrants in our industry~~organizations;

●•costs ~~difficulties~~associated orwith ~~delays~~protecting inour ~~the~~trade ~~development,~~secrets ~~production, manufacturing~~ and ~~marketing~~enforcing ofour ~~new~~patent, orcopyright ~~existing products~~ and ~~services~~trademark rights, ~~including~~and ~~difficulties~~successful orchallenges ~~delays~~to ~~associated~~the ~~with~~validity ~~obtaining~~of ~~requisite~~our ~~regulatory~~patents, ~~approvals~~copyrights or ~~clearances associated with those activities~~trademarks;

●•actions ~~changes~~of inregulatory ~~laws~~bodies and ~~regulations~~other orgovernment inauthorities, including the ~~interpretation~~FDA orand ~~application~~foreign ofcounterparts, ~~laws~~which orcould ~~regulations~~delay, aslimit ~~well~~or assuspend ~~possible~~product ~~failures~~development, tomanufacturing ~~comply~~or ~~with~~sales ~~applicable laws~~ or ~~regulations~~result asin arecalls, ~~result~~seizures, ofconsent ~~possible~~decrees, ~~misinterpretations~~injunctions orand ~~misapplications~~monetary sanctions;

●•costs ~~cost-containment~~or ~~efforts~~claims ofresulting from potential errors or defects in our ~~customers,~~manufacturing ~~purchasing~~that ~~groups~~may injure persons or damage property or operations, ~~third-party~~including ~~payers~~costs ~~and~~from ~~governmental~~remediation ~~organizations~~efforts or recalls;

●•the ~~costs~~results, ~~associated~~consequences, ~~with~~effects ~~protecting~~or ~~our~~timing ~~trade~~of ~~secrets~~any ~~and~~commercial ~~enforcing~~disputes, ~~our~~ patent, ~~copyright~~infringement ~~and~~claims ~~trademark~~or ~~rights,~~other ~~and~~legal ~~successful~~proceedings ~~challenges~~or toany ~~the~~government ~~validity of our patents, copyrights or trademarks~~investigations;

●•changes ~~actions~~in ofour ~~regulatory~~production ~~bodies and other government authorities~~capacity, including ~~the~~interruptions ~~FDA~~in ~~and~~our ~~foreign~~ability ~~counterparts,~~to ~~that~~manufacture ~~could~~our ~~delay,~~products ~~limit~~ or ~~suspend~~an ~~product~~inability ~~development,~~to ~~manufacturing~~obtain orkey ~~sales~~components or ~~result~~raw inmaterials ~~recalls,~~or ~~seizures,~~increased ~~consent~~costs ~~decrees,~~in ~~injunctions~~such ~~and~~key ~~monetary~~components ~~sanctions~~or raw materials;

●•the ~~costs~~risk orthat ~~claims~~third ~~resulting~~parties ~~from~~may ~~potential~~fail ~~errors~~to oruphold ~~defects~~their incontractual ~~our~~obligations ~~manufacturing~~or ~~that~~meet ~~may~~expected ~~injure~~deadlines, ~~persons~~which orcould ~~damage~~disrupt ~~property~~our or operations, ~~including~~or ~~costs~~adversely ~~from~~affect ~~remediation~~our ~~efforts~~financial ~~or recalls~~results;

●•uncertainties ~~the~~in ~~results,~~our ~~consequences,~~industry ~~effects~~due orto ~~timing~~the effects of ~~any~~government-driven ~~commercial disputes, patent infringement claims~~ or ~~other~~mandated ~~legal~~healthcare ~~proceedings or any government investigations~~reform;

●•competitive ~~changes~~pressures in ~~our~~the ~~production~~markets ~~capacity, including interruptions~~ in ~~our~~which ~~ability~~we ~~to manufacture our products or an inability to obtain key components or raw materials or increased costs in such key components or raw materials~~operate;

●•potential ~~the~~negative ~~failure~~impacts ofresulting ~~third~~from ~~parties~~a tofuture ~~uphold~~pandemic ~~their~~or ~~contractual~~epidemic, ~~duties~~ or ~~meet~~natural ~~expected deadlines~~disaster;

●•the ~~uncertainties~~impact inon our ~~industry~~operations ~~due~~and tofinancial ~~the~~results ~~effects~~ of ~~government-driven~~any public health emergency and any related policies and actions by governments or ~~mandated~~other ~~healthcare~~third ~~reform~~parties;

●•breaches ~~competitive~~or ~~pressures~~failures inof ~~the~~our ~~markets~~or inour ~~which~~vendors’ weor ~~operate~~customers’ information technology systems or products, including by cyberattack, data leakage, unauthorized access or theft;

●•the ~~potential~~risks ~~negative~~associated ~~impacts~~with ~~resulting~~the ~~from~~integration aof ~~future~~Artificial ~~pandemic~~Intelligence (“AI”) or ~~epidemic~~Machine Learning (“ML”) into our products or business, including the risk of algorithmic errors or ~~natural~~bias, ~~disaster~~evolving and uncertain regulatory requirements applicable to AI-enabled medical devices, data privacy and security concerns arising from the use of AI or ML, and potential liability arising from AI-driven product decisions or recommendations;

● •the ~~impact~~loss ~~on our operations and financial results~~ of, ~~any~~or ~~public~~default ~~health~~by, ~~emergency~~one ~~and~~or ~~any~~more ~~related~~key ~~policies~~customers ~~and actions by governments~~ or ~~other third parties~~suppliers;

●•unfavorable ~~breaches~~changes orto ~~failures~~the terms of ~~our~~key orcustomer ~~our vendors’~~ or ~~customers’~~supplier ~~information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft~~relationships;

●•weakening ~~the~~of ~~loss~~economic ofconditions, or ~~default~~the byanticipation thereof, ~~one~~that orcould ~~more~~adversely ~~key~~affect ~~customers~~the orlevel ~~suppliers~~of demand for our products;

Table of Contents

●•increasing ~~unfavorable~~and/or ~~changes~~fluctuating totax ~~the~~and ~~terms~~interest ofrates ~~key~~as ~~customer~~well oras ~~supplier~~inflationary ~~relationships~~pressures on the U.S. and global economies;

●•geopolitical ~~weakening~~risks, ofincluding ~~economic~~international ~~conditions~~conflicts, political instability and recent or upcoming elections in the ~~anticipation~~United ~~thereof~~States (the “U.S.”) and other countries, ~~that~~which could, ~~adversely~~among ~~affect~~other things, lead to increased market volatility; and the ~~level~~impact of ~~demand~~tariffs, ~~for~~trade restrictions, export controls, and changes in trade policy, which could increase the cost of components and raw materials used in our products, disrupt our supply chain, limit our ability to sell products in international markets, or otherwise adversely affect our business and results of operations; and

●•other ~~the~~risks ~~conditions~~detailed in our filings with the U.S. Securities and ~~global~~Exchange ~~economies,~~Commission ~~including~~ (the ~~impact of increasing and/or fluctuating tax and interest rates as well as inflationary pressures on such economies;~~“SEC”).

●These ~~geopolitical~~forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements should, therefore, be considered in light of various factors, including ~~tariffs~~those set forth under “Part I, ~~trade~~Item ~~disputes~~2. Management's Discussion and Analysis of Financial Condition and Results of Operations,” ~~international~~“Part ~~conflicts~~II, ~~recent~~Item or1A. ~~upcoming~~Risk ~~elections~~Factors,” and elsewhere in ~~the~~this ~~United~~Quarterly ~~States~~Report, and ~~other~~under ~~countries~~“Part I, Item 1A. Risk Factors” and ~~the~~“Part ~~impact~~II, ofItem ~~insufficient~~7. ~~governmental~~Management's ~~funding~~Discussion and ~~related~~Analysis ~~operational~~of ~~inefficiencies,~~Financial ~~which~~Condition ~~could~~and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~among~~2025 (the “2025 Annual Report”) and those set forth from time to time in our other ~~things~~filings with the SEC. These documents are available through our website or through the SEC's Electronic Data Gathering and Analysis Retrieval system at http://www.sec.gov. In light of such risks and uncertainties, ~~lead~~we caution you not to ~~increased~~place ~~volatility~~undue inreliance on these forward-looking statements. These forward-looking statements speak only as of the ~~financial~~date ~~market~~of ~~and~~this inQuarterly Report, or if earlier, as of the ~~market~~date they were made. The Company undertakes no obligation to publicly update or revise any forward-looking statement contained in ~~which~~this weQuarterly ~~operate~~Report, ~~our~~whether ~~business;~~as ~~and~~a result of new information, future developments, or otherwise, except as required by applicable law.

● other risks detailed in our filings with the United States Securities and Exchange Commission (the “SEC”).

These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements should, therefore, be considered in light of various factors, including those set forth under “Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations,” “Part II, Item 1A. Risk Factors,” and elsewhere in this Quarterly Report, and under “Part I, Item 1A. Risk Factors” and “Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) and those set forth from time to time in our other filings with the SEC. These documents are available through our website or through the SEC's Electronic Data Gathering and Analysis Retrieval system at http://www.sec.gov. In light of such risks and uncertainties, we caution you not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report, or if earlier, as of the date they were made. We do not intend to, and disclaim any obligation to, update or revise any forward-looking statements unless required by securities law.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “IRADIMED,” the “Company,” “we,” “our,” and “us” refer to IRADIMED CORPORATION.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

IRADIMED CORPORATION

CONDENSED BALANCE SHEETS

(in thousands)


			March 31,2026			December 31,2025
	September 30,			December 31,
			(unaudited)			(audited)
	2025			2024
ASSETS
	(unaudited)			(audited)
Current assets:
ASSETS
Cash and cash equivalents			$	56,374		$	51,159
Current assets:
Accounts receivable, net of allowance for credit losses of $231 as of March 31, 2026, and $191 as of December 31, 2025			13,415			13,667
Cash and cash equivalents	$	56,526,151		$	52,233,907
Inventory, net			11,883			11,620
Accounts receivable, net of allowance for credit losses of $191,175 as of September 30, 2025, and $274,300 as of December 31, 2024		13,858,292			10,556,733
Prepaid expenses and other current assets			1,625			1,646
Inventory, net		11,734,822			10,401,889
Prepaid income taxes			3,125			3,111
Prepaid expenses and other current assets		1,097,330			1,513,680
Total current assets			86,422			81,203
Prepaid income taxes		1,702,410			536,010
Property and equipment, net			24,225			23,856
Total current assets		84,919,005			75,242,219
Intangible assets, net			3,286			3,384
Property and equipment, net		23,792,441			16,810,797
Deferred tax asset, net			231			94
Intangible assets, net		3,373,478			3,098,691
Other assets			225			239
Operating lease right-of-use asset		—			154,688
Total assets			$	114,389		$	108,776
Deferred tax asset, net		2,422,481			2,820,468
LIABILITIES AND STOCKHOLDERS’ EQUITY
Other assets		214,374			198,912
Current liabilities:
Total assets	$	114,721,779		$	98,325,775
Accounts payable			$	2,182		$	1,820
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accrued payroll and benefits			2,066			3,218
Current liabilities:
Other accrued taxes			427			313
Accounts payable	$	2,333,474		$	1,896,405
Warranty reserve			144			144
Accrued payroll and benefits		4,071,176			3,771,756
Deferred revenue			3,397			2,871
Other accrued taxes		296,207			162,998
Accrued income taxes			3,902			1,814
Warranty reserve		137,025			118,269
Total current liabilities			12,118			10,180
Deferred revenue		3,158,065			2,259,616
Deferred revenue, non-current			3,757			3,978
Current portion of operating lease liabilities		—			153,264
Total liabilities			$	15,875		14,158
Other current liabilities		—			150,000
Stockholders’ equity:
Accrued income taxes		2,800,970			—
Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,782,837 shares issued and outstanding as of March 31, 2026, and 12,781,774 shares issued and outstanding as of December 31, 2025			$	1		$	1
Total current liabilities		12,796,917			8,512,308
Additional paid-in capital			31,020			30,386
Deferred revenue, non-current		3,572,891			2,993,287
Retained earnings			67,493			64,231
Operating lease liabilities, non-current		—			1,424
Total stockholders' equity			98,514			94,618
Total liabilities	$	16,369,808		$	11,507,019
Total liabilities and stockholders’ equity			$	114,389		$	108,776
Stockholders’ equity:
Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,721,156 shares issued and outstanding as of September 30, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024	$	1,272		$	1,271
Additional paid-in capital		32,007,647			30,026,734
Retained earnings		66,343,052			56,790,751
Total stockholders' equity		98,351,971			86,818,756
Total liabilities and stockholders’ equity	$	114,721,779		$	98,325,775

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)


			Three Months EndedMarch 31,
	Three Months Ended					Nine Months Ended
			2026					2025
	September 30,					September 30,
Revenue			$	21,979				$	19,511
	2025			2024		2025			2024
Cost of revenue			5,165					4,668
Revenue	$	21,202,064		$	18,325,959	$	61,122,101		$	53,852,954
Gross profit			16,814					14,843
Cost of revenue		4,707,756			4,134,253		13,829,995			12,263,932
Operating expenses:
Gross profit		16,494,308			14,191,706		47,292,106			41,589,022
General and administrative			4,569					4,611
Operating expenses:
Sales and marketing			4,052					4,176
General and administrative		4,355,636			3,967,799		13,246,461			12,063,971
Research and development			956					624
Sales and marketing		4,630,560			3,795,320		12,816,473			11,098,945
Total operating expenses			9,577					9,411
Research and development		674,362			639,467		2,175,969			2,261,596
Income from operations			7,237					5,432
Total operating expenses		9,660,558			8,402,586		28,238,903			25,424,512
Other income, net			532					513
Income from operations		6,833,750			5,789,120		19,053,203			16,164,510
Income before provision for income taxes			7,769					5,945
Other income, net		463,976			629,201		1,517,196			1,766,572
Provision for income tax expense			1,951					1,258
Income before provision for income taxes		7,297,726			6,418,321		20,570,399			17,931,082
Net income			$	5,818				$	4,687
Provision for income tax expense		1,721,074			1,368,830		4,532,357			3,843,834
Net income per share:
Net income	$	5,576,652		$	5,049,491	$	16,038,042		$	14,087,248
Basic			$	0.46				$	0.37
Net income per share:
Diluted			$	0.45				$	0.37
Basic	$	0.44		$	0.40	$	1.26		$	1.11
Weighted average shares outstanding:
Diluted	$	0.43		$	0.40	$	1.25		$	1.10
Basic			12,783					12,714
Weighted average shares outstanding:
Diluted			12,870					12,826
Basic		12,720,812			12,669,741		12,716,994			12,665,743
Diluted		12,860,077			12,778,446		12,842,003			12,762,346

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(in thousands)


		Common Stock										AdditionalPaid-inCapital		RetainedEarnings		Stockholders’Equity
					Additional
		Shares					Amount
	Common Stock				Paid-in			Retained		Stockholders’
Balances, December 31, 2025		12,782					$	1				$	30,386	$	64,231	$	94,618
	Shares		Amount		Capital			Earnings		Equity
Net income		—					—					—		5,818		5,818
Balances, December 31, 2024	12,709,860		$	1,271	$	30,026,734		$	56,790,751	$	86,818,756
Dividends declared		—					—					—		(2,556)		(2,556)
Net income	—			—		—			4,687,429		4,687,429
Stock-based compensation expense		—					—					684		—		684
Dividends declared	—			—		—			(2,161,522)		(2,161,522)
Net share settlement of restricted stock units		1					—					(50)		—		(50)
Stock-based compensation expense	—			—		826,064			—		826,064
Balances, March 31, 2026		12,783					1					31,020		67,493		98,514
Net share settlement of restricted stock units	5,249			1		(116,298)			—		(116,297)
Balances, March 31, 2025	12,715,109		$	1,272	$	30,736,500		$	59,316,658	$	90,054,430

Net income	—			—		—			5,773,961		5,773,961
Dividends declared	—			—		—			(2,161,628)		(2,161,628)
Stock-based compensation expense	—			—		730,618			—		730,618
Net share settlement of restricted stock units	4,893			—		(95,995)			—		(95,995)
Balances, June 30, 2025	12,720,002		$	1,272	$	31,371,123		$	62,928,991	$	94,301,386

Net income	—			—		—			5,576,652		5,576,652
Dividends declared	—			—		—			(2,162,591)		(2,162,591)
Stock-based compensation expense	—			—		666,083			—		666,083
Net share settlement of restricted stock units	1,154			—		(29,559)			—		(29,559)
Balances, September 30, 2025	12,721,156		$	1,272	$	32,007,647		$	66,343,052	$	98,351,971


	Common Stock			Additional Paid-in Capital		Retained Earnings		Stockholders’ Equity
	Shares	Amount
Balances, December 31, 2024	12,710	$	1	$	30,027	$	56,791	$	86,819
Net income	—	—		—		4,687		4,687
Dividends declared	—	—		—		(2,162)		(2,162)
Stock-based compensation expense	—	—		826		—		826
Net share settlement of restricted stock units	5	—		(116)		—		(116)

Balances, March 31, 2025	12,715	1		30,737		59,316		90,054


				Additional
	Common Stock			Paid-in		Retained		Stockholders’
	Shares	Amount		Capital		Earnings		Equity
Balances, December 31, 2023	12,660,313	$	1,265	$	28,160,745	$	43,258,154	$	71,420,164
Net income	—		—		—		4,136,533		4,136,533
Stock-based compensation expense	—		—		628,640		—		628,640
Net share settlement of restricted stock units	3,872		1		(63,876)		—		(63,875)
Balances, March 31, 2024	12,664,185	$	1,266	$	28,725,509	$	47,394,687	$	76,121,462

Net income	—		—		—		4,901,224		4,901,224
Dividends declared	—		—		—		(1,899,644)		(1,899,644)
Stock-based compensation expense	—		—		609,096		—		609,096
Net share settlement of restricted stock units	4,581		1		(63,946)		—		(63,945)
Exercise of stock options	335		—		3,296		—		3,296
Balances, June 30, 2024	12,669,101	$	1,267	$	29,273,955	$	50,396,267	$	79,671,489

Net income	—		—		—		5,049,491		5,049,491
Dividends declared	—		—		—		(1,900,487)		(1,900,487)
Stock-based compensation expense	—		—		629,965		—		629,965
Net share settlement of restricted stock units	811		—		(17,833)		—		(17,833)
Balances, September 30, 2024	12,669,912	$	1,267	$	29,886,087	$	53,545,271	$	83,432,625

See accompanying notes to unaudited condensed financial statements.

Table of Contents

~~IRADIMED~~4IRADIMED CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Three Months EndedMarch 31,
	Nine Months Ended
	2026				2025
	September 30,
Operating activities:
	2025		2024
Net income	$	5,818			$	4,687
Operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net income	$	16,038,042	$	14,087,248
Allowance for credit losses	40				(15)
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for excess and obsolete inventory	15				(38)
Allowance for credit losses		(83,125)		(91,398)
Depreciation & amortization	455				194
Provision for excess and obsolete inventory		26,667		202,140
Stock-based compensation	684				826
Depreciation & amortization		785,320		622,790
Deferred income taxes, net	(137)				130
Loss on disposal of property and equipment		34,152		3,872
Changes in operating assets and liabilities:
Stock-based compensation		2,222,764		1,867,701
Accounts receivable	212				(2,135)
Deferred income taxes, net		397,987		(591,829)
Inventory	(534)				(120)
Changes in operating assets and liabilities:
Prepaid income taxes	(14)				—
Accounts receivable		(3,218,434)		1,950,885
Prepaid expenses and other current assets	21				506
Inventory		(1,430,911)		1,278,208
Other assets	13				(7)
Prepaid income taxes		(1,166,400)		—
Accounts payable	362				694
Prepaid expenses and other current assets		416,350		244,606
Accrued payroll and benefits	(1,152)				(1,505)
Other assets		(15,462)		(2,764)
Other accrued taxes	114				94
Accounts payable		437,069		(473,820)
Deferred revenue	305				547
Accrued payroll and benefits		299,420		509,123
Other current liabilities	—				(150)
Other accrued taxes		133,209		90,447
Accrued income taxes	2,088				584
Warranty reserve		18,756		740
Net cash provided by operating activities	8,290				4,292
Deferred revenue		1,478,053		(60,555)
Investing activities:
Other current liabilities		(150,000)		—
Purchases of property and equipment	(403)				(3,697)
Accrued income taxes		2,800,970		—
Capitalized intangible assets	(66)				(220)
Net cash provided by operating activities		19,024,428		19,637,394
Net cash used in investing activities	(469)				(3,917)
Investing activities:
Financing activities:
Purchases of property and equipment		(7,470,826)		(5,214,859)
Dividends paid	(2,556)				(2,162)
Capitalized intangible assets		(533,767)		(545,198)
Taxes paid related to the net share settlement of equity awards	(50)				(116)
Net cash used in investing activities		(8,004,593)		(5,760,057)
Net cash used in financing activities	(2,606)				(2,278)
Financing activities:
Net increase (decrease) in cash and cash equivalents	5,215				(1,903)
Dividends paid		(6,485,741)		(11,776,128)
Cash and cash equivalents, beginning of period	51,159				52,234
Proceeds from exercises of stock options		—		3,296
Cash and cash equivalents, end of period	$	56,374			$	50,331
Taxes paid related to the net share settlement of equity awards		(241,850)		(145,652)
Supplemental disclosure of cash flow information:
Net cash used in financing activities		(6,727,591)		(11,918,484)
Cash paid for income taxes	$	14			$	9
Net increase in cash and cash equivalents		4,292,244		1,958,853
Cash and cash equivalents, beginning of period		52,233,907		49,762,198
Cash and cash equivalents, end of period	$	56,526,151	$	51,721,051
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	2,499,800	$	4,456,827
ROU asset and liability adjustment	$	—	$	1,486,093
Operating and short-term lease payments recorded within cash flow provided by operating activities	$	367,378	$	612,910

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

Notes to Unaudited Condensed Financial Statements

1 — Basis of Presentation

The accompanying interim unaudited condensed financial statements of IRADIMED CORPORATION (“IRADIMED,” the “Company,” “we,” “our” and “us”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~ 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2025~~ 2026, and other interim periods, or future years or periods.

The accompanying interim unaudited condensed financial statements should be read in conjunction with the financial statements and related footnotes to financial statements included in our ~~2024~~2025 Annual Report. The accounting policies followed in the preparation of these interim condensed financial statements, except as described in Note 1 herein, are consistent in all material respects with those described in Note 1 to the Financial Statements in the ~~2024~~2025 Annual Report.

We operate in one reportable segment, which develops, manufactures, markets, sells, and distributes innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices ~~and products~~, related accessories, disposables, and service for use primarily by hospitals and acute care facilities during MRI procedures. We are a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

Certain Significant Risks and Uncertainties

We market our products to end users in the ~~United~~U.S. ~~States~~ and to third-party distributors internationally. Sales to end users in the ~~United~~U.S. ~~States~~ are generally made on open credit terms. Management maintains an allowance for potential credit losses.

We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits regularly throughout the year. We have not incurred any losses related to these balances.

Our medical devices require clearance from the FDA and international regulatory agencies prior to commercialized sales. Our future products may not receive required ~~clearances~~clearance. If we were denied such clearances, or if such clearances were revoked or delayed or if we were unable to timely renew certain clearances for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.

Certain key components ~~of our products~~ essential to ~~their~~the functionality of our products are obtained from sole-~~sourced~~source suppliers. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.

Table of Contents

2 — Revenue Recognition

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.

Table of Contents

Revenue information by geographic region is as follows:


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
United States	$	18,025	$	15,953
International	3,954		3,558
Total revenue	$	21,979	$	19,511


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
United States	$	18,114,996	$	15,207,195	$	52,257,678	$	44,101,367
International		3,087,068		3,118,764		8,864,423		9,751,587
Total revenue	$	21,202,064	$	18,325,959	$	61,122,101	$	53,852,954

Revenue information by type is as follows:


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	7,664	$	5,999
MRI Compatible Patient Vital Signs Monitoring Systems	7,107		6,545
Ferro Magnetic Detection Systems	621		418
Total devices revenue	15,392		12,962
Amortization of extended maintenance agreements	659		560
Disposables	4,885		4,947
Services and other	1,043		1,042
Total revenue	$	21,979	$	19,511


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	8,333,988	$	6,952,142	$	22,520,711	$	19,026,021
MRI Compatible Patient Vital Signs Monitoring Systems		6,872,311		5,926,028		19,361,259		17,837,910
Ferro Magnetic Detection Systems		377,716		128,505		1,278,123		744,607
Total devices revenue		15,584,015		13,006,675		43,160,093		37,608,538
Amortization of extended maintenance agreements		612,993		584,218		1,765,644		1,639,537
Disposables		4,130,667		3,689,624		13,281,625		11,399,216
Services and other		874,389		1,045,442		2,914,739		3,205,663
Total revenue	$	21,202,064	$	18,325,959	$	61,122,101	$	53,852,954

Contract Liabilities

Our contract liabilities consist of:


	March 31, 2026		December 31, 2025
(in thousands)	(unaudited)		(audited)
Advance payments from customers	$	419	$	486
Shipments in-transit	231		93
Extended maintenance agreements	6,504		6,270
Total	$	7,154	$	6,849


	September 30,		December 31,
	2025		2024
	(unaudited)		(audited)
Advance payments from customers	$	773,102	$	88,099
Shipments in-transit		166,304		2,387
Extended maintenance agreements		5,791,550		5,162,417
Total	$	6,730,956	$	5,252,903

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2024	$	5,252,903
Increases due to cash received from customers		4,017,802
Decreases due to recognition of revenue		(2,539,749)
Contract liabilities, September 30, 2025	$	6,730,956


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2023	$	5,360,360
Increases due to cash received from customers		3,353,763
Decreases due to recognition of revenue		(3,410,723)
Contract liabilities, September 30, 2024	$	5,303,400

Table of Contents


	Deferred Revenue
(in thousands)	(unaudited)
Contract liabilities, December 31, 2025	$	6,849
Increases due to cash received from customers	1,917
Decreases due to recognition of revenue	(1,612)
Contract liabilities, March 31, 2026	$	7,154


	Deferred Revenue
(in thousands)	(unaudited)
Contract liabilities, December 31, 2024	$	5,253
Increases due to cash received from customers	1,306
Decreases due to recognition of revenue	(759)
Contract liabilities, March 31, 2025	$	5,800

Capitalized Contract Costs

Our capitalized contract costs totaled $~~214,374~~225 thousand and $~~179,597~~239 thousand as of ~~September~~March 3031, ~~2025~~ 2026 and December 31, ~~2024~~ 2025, respectively, and are classified as other assets on the unaudited condensed balance sheets.

3 — Basic and Diluted Net Income per Share

Basic net income per share is based upon the weighted-average number of shares of Company common stock, par value $0.0001 per share (“common stock”), outstanding during the period. Diluted net income per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options, restricted stock units and performance-based restricted stock units granted by us represent the only dilutive effect reflected in diluted weighted-average shares of common stock outstanding.

The following table presents the computation of basic and diluted net income per share of common stock:


	Three Months Ended March 31,
	2026		2025
(in thousands, except per share data)	(unaudited)
Net income	$	5,818	$	4,687
Weighted-average shares outstanding — Basic	12,783		12,714
Effect of dilutive securities:

Restricted stock units	45		53
Performance-based restricted stock units	42		59
Weighted-average shares outstanding — Diluted	12,870		12,826
Basic net income per share	$	0.46	$	0.37
Diluted net income per share	$	0.45	$	0.37


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
Net income	$	5,576,652	$	5,049,491	$	16,038,042	$	14,087,248
Weighted-average shares outstanding — Basic		12,720,812		12,669,741		12,716,994		12,665,743
Effect of dilutive securities:
Stock options		—		2,104		—		2,223
Restricted stock units		71,157		63,929		61,839		55,870
Performance-based restricted stock units		68,108		42,672		63,170		38,510
Weighted-average shares outstanding — Diluted		12,860,077		12,778,446		12,842,003		12,762,346
Basic net income per share	$	0.44	$	0.40	$	1.26	$	1.11
Diluted net income per share	$	0.43	$	0.40	$	1.25	$	1.10

Restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:


	Three Months Ended March 31,
(in thousands)	2026	2025
	(unaudited)
Anti-dilutive restricted stock units	5	—


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2025	2024	2025	2024
	(unaudited)		(unaudited)
Anti-dilutive restricted stock units	182	7	61	13

Anti-dilutive shares for the quarter ended March 31, 2026 increased compared to the same period in the prior year, primarily due to new restricted stock unit (RSU) grants to executives that were issued earlier than in the prior years, when such grants were made in the fourth quarter of 2024. The fair value of these RSUs at their respective grant dates exceeded their fair value at the end of the current quarter and excluded from the diluted earnings per share calculation.

4 — Inventory, net

Inventory consists of:


	March 31,		December 31,
	2026		2025
(in thousands)	(unaudited)		(audited)
Raw materials	$	10,023	$	9,612
Work in process	564		831
Finished goods	1,866		1,732
Inventory before allowance for excess and obsolete	12,453		12,175
Allowance for excess and obsolete	570		555
Total	$	11,883	$	11,620


	September 30,		December 31,
	2025		2024
	(unaudited)		(audited)
Raw materials	$	9,590,716	$	9,022,690
Work in process		735,775		568,540
Finished goods		1,943,369		1,319,030
Inventory before allowance for excess and obsolete		12,269,860		10,910,260
Allowance for excess and obsolete		(535,038)		(508,371)
Total	$	11,734,822	$	10,401,889

Table of Contents

5 — Property and Equipment, net

Property and equipment consist of:


	March 31, 2026		December 31, 2025
(in thousands)	(unaudited)		(audited)
Land	$	8,105	$	8,105
Land improvements	1,409		1,409
Building	11,531		11,526
Computer software and hardware	2,231		2,187
Furniture and fixtures	2,361		2,078

Machinery and equipment	3,757		3,600
Construction in-process	194		23
	29,588		28,928
Accumulated depreciation	(5,363)		(5,072)
Total	$	24,225	$	23,856


	September 30,		December 31,
	2025		2024
	(unaudited)		(audited)
Land	$	8,104,987	$	6,253,790
Land improvements		1,409,336		—
Building		11,526,063		—
Computer software and hardware		2,110,317		1,584,889
Furniture and fixtures		2,087,911		1,842,773
Leasehold improvements		—		270,486
Machinery and equipment		2,922,891		2,645,129
Construction in-process		497,451		8,809,237
		28,658,956		21,406,304
Accumulated depreciation		(4,866,515)		(4,595,507)
Total	$	23,792,441	$	16,810,797

Depreciation expense of property and equipment was approximately $291 thousand and $134 thousand for the three months ended March 31, 2026 and 2025, respectively.

Depreciation expense of property and equipment was $256,312 and $139,840 for the three months ended September 30, 2025 and 2024, respectively, and $526,340 and $450,194 for the nine months ended September 30, 2025 and 2024, respectively.

During the third quarter of 2025, the Company completed the construction of a new corporate office and manufacturing facility in Orlando, Florida (the “New Facility”). Upon receiving the certificate of occupancy, associated construction in-process balances are now allocated and recognized as in-service property and equipment based on the asset type.

Property and equipment, net, information by geographic region is as follows:


	March 31, 2026		December 31, 2025
(in thousands)	(unaudited)		(audited)
United States	$	23,748	$	23,507
International	477		349
Total property and equipment, net	$	24,225	$	23,856


	September 30,		December 31,
	2025		2024
	(unaudited)		(audited)
United States	$	23,459,416	$	16,398,513
International		333,025		412,284
Total property and equipment, net	$	23,792,441	$	16,810,797

Long-lived assets held outside of the U.S. consist principally of tooling, which is a component of machinery and equipment.

Long-lived assets held outside of the United States consist principally of tooling, which is a component of machinery and equipment.

Table of Contents

6 — Intangible Assets, net

The following table summarizes the components of intangible asset balances:


	March 31, 2026		December 31, 2025
(in thousands)	(unaudited)		(audited)
Patents — in use	$	443	$	443
Patents — fully amortized	70		70
Patents — in process	74		74
Internally developed software — in use	3,950		3,934
Internally developed software — in process	424		374
Trademarks	44		44
	5,005		4,939
Accumulated amortization	(1,719)		(1,555)
Total	$	3,286	$	3,384


	September 30,		December 31,
	2025		2024
	(unaudited)		(audited)
Patents — in use	$	442,957	$	321,874
Patents — fully amortized		70,164		70,164
Patents — in process		66,333		177,023
Internally developed software — in use		3,934,033		1,840,520
Internally developed software — in process		259,570		1,835,189
Trademarks		43,547		38,067
		4,816,604		4,282,837
Accumulated amortization		(1,443,126)		(1,184,146)
Total	$	3,373,478	$	3,098,691

Amortization expense of intangible assets was approximately $164 thousand and $60 thousand for the three months ended March 31, 2026 and 2025, respectively.

Expected annual amortization expense for the remaining portion of 2026, the next five years, and thereafter related to intangible assets, excluding trademarks considered to have indefinite lives and in process intangible assets, is as follows:

Amortization expense of intangible assets was $127,410 and $57,731 for the three months ended September 30, 2025 and 2024, respectively, and $258,980 and $172,596 for the nine months ended September 30, 2025 and 2024, respectively.


(in thousands)
Nine months remaining ending December 31, 2026	$	279
2027	370
2028	367
2029	363
2030	345
2031	225
Thereafter	1,293

Expected annual amortization expense for the remaining portion of 2025, the next five years, and thereafter related to intangible assets, excluding trademarks considered to have indefinite lives and in process intangible assets, is as follows:


Three months remaining ending December 31, 2025	$	111,236
2026	$	440,180
2027	$	366,467
2028	$	363,865
2029	$	360,143
2030	$	342,170
Thereafter	$	1,019,967

7 — Segment Reporting

The Company operates in one business segment that develops, manufactures, markets, sells, and distributes MRI compatible medical devices ~~and products~~, related accessories, disposables and services relating to them. The determination to operate as a single business segment is consistent with the consolidated financial information regularly provided to the Company’s appointed chief operating decision maker (CODM), the President, Chief Executive Officer, and Chairman of the Company’s Board of Directors (the “Board”), Roger Susi. As the Company has only one operating segment and is managed on a consolidated basis, the measure of profit or loss is consolidated net income or loss. The accounting policies for our segment are the same as those described in “Note 1 - Organization and Significant Accounting Policies” in our ~~2024~~2025 Annual Report, and in Note 1 above. See the Condensed Statements of Operations.

8 — Fair Value Measurements

The fair values of cash equivalents, accounts receivables net, and accounts payable approximate their carrying amounts due to their short duration.

As of ~~September~~March 3031, ~~2025~~ 2026, we did not have any assets or liabilities subject to recurring fair value measurements.

Table of Contents

9 — Stock-Based Compensation

Stock-based compensation was recognized as follows in the unaudited Condensed Statements of Operations:


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
Cost of revenue	$	70	$	72
General and administrative	387		518
Sales and marketing	158		135
Research and development	69		101
Total	$	684	$	826


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
Cost of revenue	$	71,970	$	62,359	$	214,848	$	178,713
General and administrative		363,286		381,339		1,319,867		1,139,316
Sales and marketing		168,991		135,358		423,689		393,649
Research and development		61,836		50,908		264,361		156,023
Total	$	666,083	$	629,964	$	2,222,765	$	1,867,701

As of March 31, 2026, we had (i) $4,960 thousand of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.50 years and (ii) $662 thousand of unrecognized compensation cost related to unvested performance-based restricted stock units, which is expected to be recognized over a weighted-average period of 1.44 years.

The following table presents a summary of our equity award activity for the three months ended March 31, 2026 (shares):

As of September 30, 2025, we had (i) $3,077,208 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.18 years and (ii) $969,229 of unrecognized compensation cost related to unvested performance-based restricted stock units, which is expected to be recognized over a weighted-average period of 1.81 years.


	Three Months Ended March 31, 2026
(in thousands)	Restricted Stock Units	Performance Based Restricted Stock Units
Outstanding beginning of period	83	25
Awards granted	16	—
Awards exercised/vested	(2)	—

Outstanding end of period	97	25

The following table presents a summary of our equity award activity for the nine months ended September 30, 2025 (shares):


	Nine Months Ended
	September 30, 2025
		Performance
		Based
	Restricted	Restricted
	Stock Units	Stock Units
Outstanding beginning of period	134,816	44,251
Awards granted	4,132	—
Awards exercised/vested	(13,231)	(2,210)
Awards canceled/ forfeited	(6,104)	—
Outstanding end of period	119,613	42,041

10 — Income Taxes

For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~ 2026, we recorded a provision for income tax expense of $1,~~721,074~~951 ~~and $4,532,357, respectively~~thousand. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~ 2026, our effective tax rate was 2325.61% ~~and 22.0%~~, ~~respectively,~~ and differed from the U.S. federal statutory rate primarily due to U.S. state income tax expense, and non-deductible compensation expenses, partially offset by benefits from research and development tax credits.

For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~ 2025, we recorded a provision for income tax expense of $1,~~368,830~~258 ~~and~~thousand ~~$3,843,834, respectively~~. For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~ 2025, our effective tax rate was 21.32% ~~and 21.4%~~, ~~respectively,~~ and differed from the U.S. federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from research and development tax credits.

OnWe ~~July~~file ~~31,~~tax ~~2024,~~returns ~~the~~in ~~Company received a notice of examination from~~ the U.S. ~~Internal~~federal ~~Revenue~~jurisdiction ~~Service~~and ~~(the~~many “IU.R.S.”) ~~for~~state ~~the tax year ended December 31, 2021~~jurisdictions. OnOur ~~July~~returns ~~29,~~are ~~2025,~~not ~~the~~currently ~~Company~~under ~~received~~examination ~~notice~~by ~~that~~ the ~~I.R.S.~~Internal ~~has~~Revenue ~~completed its review of our tax return for the tax year ended December 31, 2021, with no changes to our reported tax return, and closed out its examination~~Service. The Company remains subject to income tax examinations for our U.S. federal and certain U.S. state income taxes for ~~2022~~2023 and subsequent years.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the U.S. The OBBBA includes several significant provisions, ~~such~~including as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions, such as accelerated deductions for qualified property and domestic research expenditures. The Company has evaluated the impact of the OBBBA on its financial statements and does not expect the legislation to result in a material change to its annual effective tax rate. During the first quarter of 2026, the Company implemented the OBBBA‑related changes to the foreign‑derived deduction regime, including the transition from the foreign‑derived intangible income (“FDII”) deduction to the foreign‑derived deduction‑eligible income (“FDDEI”) deduction, which became effective for tax years beginning after December 31, 2025.

Table of Contents

modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions including the acceleration of tax deductions for qualified property and research expenditures. The Company has completed an initial assessment of OBBBA’s impact on its financial statement and does not expect a material change in its annual effective rate.

11 — Leases

In January 2014, we entered into a non-cancelable operating lease, commencing on July 1, 2014, for our manufacturing and headquarters facility in Winter Springs, Florida owned by Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. On May 31, 2019, the expiration date of the initial lease term, and pursuant to the terms of the lease contract, we renewed the lease for an additional five years, which was set to expire on May 31, 2024.

On May 29, 2024, the Company entered into a lease amendment (the “Lease Amendment”) with Susi, LLC, under which the Company did not exercise the second five-year option because of the continued construction of the Company’s New Facility. Pursuant to the terms, the Lease Amendment has an expiration date of May 31, 2025, and includes an option to renew on a month-to-month basis for up to six months thereafter. We exercised the option to renew on a month-to-month basis until the move to the New Facility is completed. During the third quarter of 2025, the Company completed its move to the New Facility and terminated the month-to-month lease with Susi, LLC under the Lease Amendment.

Lease costs for short-term leases were immaterial for the three and nine months ended September 30, 2025 and 2024.

12 — Commitments and Contingencies

Purchase commitments. We had various purchase orders for goods or services totaling $9,851,492 and $7,523,859 as of September 30, 2025 and December 31, 2024, respectively. Amounts recognized in our balance sheet related to these purchase orders were immaterial.

Legal matters. From time to time, the Company is party to litigation and other legal matters incidental to the conduct of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of September 30, 2025, the Company was not involved in any such matters, individually or in the aggregate, which management believes would have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows.

13 — Subsequent Events

On October 30, 2025, the Company’s Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.17 per share of outstanding common stock. The dividend is payable to stockholders of record as of the close of business on November 14, 2025 and will be paid on November 25, 2025.

Besides the above, there were no subsequent events requiring disclosure or recognition in the Company’s unaudited condensed financial statements, other than those included elsewhere in this Quarterly Report.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited condensed financial statements and the related notes to those statements included in this Quarterly Report, the discussion of certain risks and uncertainties contained in (i) “Part I, Item 1. Business,” “Part 1, Item 1A. Risk Factors,” and the discussion under “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2024 Annual Report and (ii) “Part II, Item 1A. Risk Factors” and the “Cautionary Statements Regarding Forward-Looking Statements” section included in this Quarterly Report.

~~Table~~11 of— ~~Contents~~Commitments and Contingencies

Purchase commitments. We had various purchase orders for goods or services totaling $8,798 thousand and $9,827 thousand as of March 31, 2026 and December 31, 2025, respectively. Amounts recognized on our balance sheets related to these purchase orders were immaterial.

Legal matters. From time to time, the Company is party to litigation and other legal matters incidental to the conduct of its business. Such matters are subject to many uncertainties and outcomes cannot be predicted with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of March 31, 2026, the Company was not involved in any such matters, individually or in the aggregate, which management believes would have a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows.

12 — Subsequent Events

On April 30, 2026, the Board declared a regular quarterly cash dividend of $0.20 per share of outstanding common stock. The dividend is payable to stockholders of record as of the close of business on May 15, 2026 and will be paid on May 29, 2026.

Except as described above and elsewhere in this Quarterly Report, there were no subsequent events requiring disclosure or recognition in the Company’s unaudited condensed financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with (i) our unaudited condensed financial statements and the related notes thereto included in this Quarterly Report, (ii) discussions under "Part I, Item 1. Business,” “Part I, Item 1A. Risk Factors,” and “Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” in the 2025 Annual Report, and (iii) “Part II, Item 1A. Risk Factors” and the “Cautionary Statements Regarding Forward-Looking Statements” section included in this Quarterly Report.

Our Business

We develop, manufacture, market, sell, and distribute MRI compatible medical devices and product related accessories, disposables, and services.

We are a leader in the development of innovative MRI compatible medical devices ~~and products~~. We are the only known provider of a non-magnetic IV infusion pump ~~system~~systems ~~that is~~ specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components, which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump ~~system~~systems ~~has~~have been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump ~~solution~~solutions ~~provides~~provide a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Each IV infusion pump system generally consists of an MRidium® MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.

Our ~~patented~~ 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The ~~IRADIMED~~IRadimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The ~~IRADIMED~~IRadimed 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the ~~IRADIMED~~IRadimed 3880 include: wireless ~~Electrocardiogram~~electrocardiogram (ECG) with dynamic gradient filtering; wireless ~~blood~~peripheral oxygen saturation ~~monitoring~~ (SpO2) monitoring using Masimo® algorithms; non-magnetic respiratory carbon dioxide (CO2); invasive and non-invasive blood pressure; patient temperature; and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The ~~IRADIMED~~IRadimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

~~Our~~We ~~Model~~generate ~~3600~~revenue ~~ferromagnetic~~from ~~detection~~the ~~device,~~sale ~~IRadimed~~of ~~FMD1,~~MRI ~~with~~compatible ~~remote~~medical ~~alarm~~devices ~~logging~~and ~~unit~~accessories, ~~(“RALU”)~~extended ismaintenance agreements, ~~the~~services ~~first~~related ~~ferromagnetic~~to ~~detection~~maintaining ~~device~~our ~~with~~products ~~TruSenseTM~~and ~~threat~~the ~~qualification~~sale ~~technology.~~of ~~Our~~disposable ~~patent~~products ~~pending~~used ~~TruSenseTM~~with ~~technology~~our ~~predicts~~devices. anThe ~~approaching~~principal ~~ferrous~~customers ~~hazard~~for byour ~~uniquely~~MRI ~~sensing~~compatible aproducts ~~threat’s~~include ~~speed,~~hospitals ~~trajectory,~~ and ~~MRI~~acute ~~Zone~~care IVfacilities, ~~door~~both ~~status with IRADIMED’s expertise~~ in ~~Dynamic~~the ~~Signal Processing~~U. ~~This technology reduces false alarms, all while simultaneously circumventing background magnetic field noise~~S. ~~The Model 3600 FMD1 can be self-installed~~ and ~~does~~internationally. ~~not~~As ~~require~~of ~~drilling~~March 31, ~~special tools~~2026, ~~permits~~our ordirect ~~contractors~~U.S. ~~like~~sales ~~traditional~~force ~~FMD~~consisted ~~systems.~~of ~~The~~29 ~~wireless~~field ~~touchscreen,~~sales ~~RALU~~representatives, is4 ~~unique~~regional insales ~~the~~directors ~~industry~~ and ~~provides~~supplemented aby ~~full~~10 ~~color~~clinical ~~visual~~application ~~representation of the MRI door and FMD status~~specialists. ~~When an incident occurs~~Internationally, ~~this~~we ~~wireless~~have ~~touchscreen~~distribution ~~uniquely~~agreements ~~allows~~with ~~users~~independent todistributors ~~quickly~~selling ~~and~~our ~~easily log all ferrous items as they enter the MRI Zone IV improving the reporting accuracy hospitals require for accreditation~~products.

WeSelling ~~generate~~cycles ~~revenue~~for ~~from~~our ~~the~~devices ~~sale~~have ofvaried ~~MRI~~widely ~~compatible~~and ~~medical~~have ~~devices~~historically ranged between three and ~~related~~six ~~products,~~months ~~accessories,~~in ~~extended~~duration. ~~maintenance~~We also enter into agreements with integrated delivery networks (“IDNs”) and healthcare supply contracting companies, ~~services~~which ~~related~~are commonly referred to ~~maintaining~~as ~~our~~group ~~products~~purchasing ~~and~~organizations (“GPOs”) in the ~~sale~~U.S., ofwhich ~~disposable~~enable ~~products~~us ~~used~~to ~~with~~sell and distribute our ~~devices.~~products ~~The~~to ~~principal~~their ~~customers~~member ~~for~~hospitals. ~~our~~GPOs ~~MRI~~negotiate ~~compatible~~volume ~~products~~purchase ~~include~~prices for hospitals, ~~and~~group ~~acute~~practices, ~~care~~and ~~facilities,~~other ~~both~~clinics inthat ~~the~~are ~~United~~members ~~States~~of ~~and~~a ~~internationally~~GPO. AsUnder ofour ~~September 30~~GPO agreements, ~~2025,~~ ~~our~~we ~~direct~~are ~~U.S.~~required ~~sales~~to ~~force~~pay ~~consisted~~the ofGPOs 29a ~~field~~fee ~~sales~~of ~~representatives,~~three 4percent ~~regional~~of the sales ~~directors~~of ~~and~~our ~~supplemented~~products byto 9members ~~clinical~~of ~~application~~the ~~specialists~~GPO. Sales ~~Internationally,~~to weparticipating ~~have~~IDNs ~~distribution~~do ~~agreements~~not ~~with~~have ~~independent~~an ~~distributors~~associated ~~selling our products~~fee.

Selling cycles for our devices have varied widely and have historically ranged between three and six months in duration. We also enter into agreements with integrated delivery networks (“IDNs”) and healthcare supply contracting companies, which are commonly referred to as group purchasing organizations (“GPOs”) in the U.S., which enable us to 18

Table of Contents

sell and distribute our products to their member hospitals. GPOs negotiate volume purchase prices for hospitals, group practices, and other clinics that are members of a GPO. Under our GPO agreements, we are required to pay the GPOs a fee of three percent of the sales of our products to members of the GPO. Sales to participating IDNs do not have an associated fee.

Financial Highlights

For the quarter ended ~~September~~March 3031, ~~2025~~ 2026, our revenue increased by $2.95 million, or 1613% to $2122.20 million, compared to $1819.35 million for the quarter ended ~~September~~March 3031, ~~2024~~ 2025. Income before the provision for income taxes was $7.38 million for the quarter ended ~~September~~March 3031, ~~2025~~ 2026, compared to $65.49 million for the quarter ended ~~September~~March 3031, ~~2024~~ 2025. Net income was $5.68 million, or $0.4345 per diluted share, in the quarter ended ~~September~~March 3031, ~~2025~~ 2026, compared to $54.07 million, or $0.4037 per diluted share in the quarter ended ~~September~~March 3031, ~~2024~~ 2025.

For the ~~remainder of~~ fiscal year ~~2025~~2026, we expect higher revenue when compared to the ~~same~~fiscal ~~period~~year in2025 ~~2024~~ primarily due to higher sales of our medical devices and products, related accessories, disposables, and services. We also expect higher operating expenses compared to the ~~same~~fiscal ~~period~~year in2025 ~~2024~~ primarily due to higher sales and marketing, regulatory, and general and administrative expenses.

Recent Developments and Trends

In addition to the trends identified in the ~~2024~~2025 Annual Report under “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Q2 2025 Quarterly Report”) under “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our business in fiscal year ~~2025~~2026 has been impacted, and we believe will continue to be impacted, by the recent developments and trends stated therein and herein.

In February 2026, the Supreme Court of the United States issued a ruling determining that certain tariffs were not lawfully imposed. As a result of this decision, impacted importers may be entitled to seek refunds of previously paid tariffs, subject to applicable administrative processes and further governmental actions. The Company has incurred costs associated with tariffs on certain imported materials and components and is evaluating its eligibility to pursue refunds. While the ruling may provide a basis for recovery of certain amounts previously paid, the timing, process, and ultimate realization of any such refunds remain uncertain and may be subject to additional regulatory guidance or legal developments. The Company cannot reasonably estimate the financial impact of this matter, including the amount or timing of any potential refunds at this time and will continue to assess developments and their potential impact on its business, financial condition, and results of operations.

~~Additionally,~~The ~~the~~ Company continues to monitor ongoing ~~changes~~geopolitical todevelopments, including the current conflicts in the Middle East, and the potential impacts on global trade policies and economic conditions. These events have contributed to increased uncertainty in international markets, including ~~the~~potential ~~imposition~~disruptions to supply chains, fluctuations in commodity and transportation costs, and evolving trade regulations. The Company has not experienced a material adverse impact on its operations or financial condition as a direct result of ~~tariffs~~these developments. However, the situation remains dynamic, and the extent to which these geopolitical events may affect the Company’s isbusiness, ~~implementing~~results ~~plans~~of operations, or financial condition in future periods remains uncertain. The Company will continue to ~~mitigate~~actively ~~related~~assess ~~impacts~~potential ~~associated~~risks ~~with~~and ~~the~~implement ~~tariffs~~mitigation strategies, where appropriate, to address any emerging impacts.

On May 29, 2025, the Company announced that the FDA has granted 510(k) clearance for the Company’s next-generation MRidium® 3870 IV infusion pump system (the “MRidium® 3870”).

The MRidium® 3870 is an advanced, MRI compatible infusion pump that extends the Company’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, addressing growing demands for safe and reliable fluid delivery in diagnostic imaging. The MRidium® 3870 features a non-magnetic ultrasonic pump motor, non-interfering radio frequency emissions, and non-ferrous components, ensuring seamless performance in high-magnetic-field environments.

The Company plans an initial strategic rollout of the newly FDA-cleared MRidium® 3870 infusion pump to select healthcare facilities in the fourth quarter of 2025, with product shipments growing towards full commercial distribution throughout 2026.

On July 4, 2025 OBBBA was enacted in the U.S. OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions including the acceleration of tax deductions for qualified property and research expenditures. The Company has completed an initial assessment of OBBBA’s impact on its financial statement and does not expect a material change in its annual effective rate.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed financial statements, which we have prepared in accordance with GAAP. The preparation of these unaudited condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

18We believe that the estimates, assumptions and judgments involved in the accounting policies described in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2025 Annual Report have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. As of March 31, 2026, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the 2025 Annual Report.

~~Table of Contents~~19

statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2024 Annual Report have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. As of September 30, 2025, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the 2024 Annual Report.

Results of Operations

The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Our historical operating results are not necessarily indicative of the results for any future period.


	Percent of Revenue
	Three Months Ended March 31,
	2026		2025
	(unaudited)
Revenue	100.0	%	100.0	%
Cost of revenue	23.5		23.9
Gross profit	76.5		76.1
Operating expenses:
General and administrative	20.8		23.6
Sales and marketing	18.4		21.4
Research and development	4.3		3.2
Total operating expenses	43.6		48.2
Income from operations	32.9		27.8
Other income, net	2.4		2.6
Income before provision for income taxes	35.3		30.5
Provision for income tax expense	8.9		6.4
Net income	26.5	%	24.0	%


	Percent of Revenue				Percent of Revenue
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
Revenue	100.0	%	100.0	%	100.0	%	100.0
Cost of revenue	22.2		22.6		22.6		22.8
Gross profit	77.8		77.4		77.4		77.2
Operating expenses:
General and administrative	20.6		21.7		21.7		22.4
Sales and marketing	21.8		20.7		21.0		20.6
Research and development	3.2		3.5		3.6		4.2
Total operating expenses	45.6		45.9		46.3		47.2
Income from operations	32.2		31.6		31.1		30.0
Other income, net	2.2		3.4		2.5		3.3
Income before provision for income taxes	34.4		35.0		33.6		33.3
Provision for income tax expense	8.1		7.5		7.4		7.1
Net income	26.3	%	27.5	%	26.2	%	26.2

Comparison of the Three Months Ended March 31, 2026 and 2025

Comparison of the Three Months Ended and the Nine Months Ended September 30, 2025 and 2024

Revenue by Geographic Region


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
United States	$	18,025	$	15,953
International	3,954		3,558
Total revenue	$	21,979	$	19,511


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
	(unaudited)				(unaudited)
United States	$	18,114,996	$	15,207,195	$	52,257,678	$	44,101,367
International		3,087,068		3,118,764		8,864,423		9,751,587
Total revenue	$	21,202,064	$	18,325,959	$	61,122,101	$	53,852,954

Table of Contents

Revenue by Type


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Devices:	(unaudited)				(unaudited)
MRI Compatible IV Infusion Pump Systems	$	8,333,988	$	6,952,142	$	22,520,711	$	19,026,021
MRI Compatible Patient Vital Signs Monitoring Systems		6,872,311		5,926,028		19,361,259		17,837,910
Ferro Magnetic Detection Systems		377,716		128,505		1,278,123		744,607
Total devices revenue		15,584,015		13,006,675		43,160,093		37,608,538
Amortization of extended maintenance agreements		612,993		584,218		1,765,644		1,639,537
Disposables		4,130,667		3,689,624		13,281,625		11,399,216
Services and other		874,389		1,045,442		2,914,739		3,205,663
Total revenue	$	21,202,064	$	18,325,959	$	61,122,101	$	53,852,954

For the three months ended September 30, 2025, total revenue increased by $2.9 million, or 16%, to $21.2 million from $18.3 million for the same period in 2024. This increase is primarily attributed to continued demand for our IV infusion pump system, disposables, amortization of extended maintenance revenue, and modifications to our sales incentive plan for patient vital signs monitoring systems.

Revenue from sales in the U.S. increased by $2.9 million, or 19%, to $18.1 million for the three months ended September 30, 2025, from $15.2 million for the same period in 2024. Revenue from sales internationally remained constant for the three months ended September 30, 2025 and 2024 at $3.1 million. Domestic sales accounted for 85% of revenue for the three months ended September 30, 2025, compared to 83% for the same period in 2024.

Revenue from sales of devices increased by $2.6 million, or 20%, to $15.6 million for the three months ended September 30, 2025, from $13.0 million for the same period in 2024. Revenue from the amortization of extended maintenance agreements increased by $29 thousand, or 5%, to $613 thousand for the three months ended September 30, 2025, from $584 thousand for the three months ended September 30, 2024. Revenue from sales of our disposables increased by $0.4 million, or 12%, to $4.1 million for the three months ended September 30, 2025, from $3.7 million for the same period in 2024. Revenue from the services and other decreased by $171 thousand, or 16%, to $0.9 million for the three months ended September 30, 2025, from $1.0 million for the three months ended September 30, 2024.

For the nine months ended September 30, 2025, total revenue increased by $7.2 million, or 13%, to $61.1 million from $53.9 million for the same period in 2024. This increase is primarily attributed to continued demand for our IV infusion pump system, disposables, amortization of extended maintenance revenue, and modification to sales incentive plan for patient vital signs monitoring systems.

Revenue from sales in the U.S. increased by $8.2 million, or 18%, to $52.3 million for the nine months ended September 30, 2025, from $44.1 million for the same period in 2024. Revenue from sales internationally decreased by $0.9 million, or 9%, for the nine months ended September 30, 2025 to $8.9 million, from $9.8 million for the same period in 2024. Domestic sales accounted for 85% of revenue for the nine months ended September 30, 2025, compared to 82% for the same period in 2024.

Revenue from sales of devices increased by $5.6 million, or 15%, to $43.2 million for the nine months ended September 30, 2025, from $37.6 million for the same period in 2024. Revenue from the amortization of extended maintenance agreements increased by $126 thousand, or 8%, to $1.8 million for the nine months ended September 30, 2025, from $1.6 million for the nine months ended September 30, 2024. Revenue from sales of our disposables increased by $1.9 million, or 17%, to $13.3 million for the nine months ended September 30, 2025, from $11.4 million for the same period in 2024. Revenue from the services and other decreased by $0.3 million, or 9%, to $2.9 million for the nine months ended September 30, 2025, from $3.2 million for the nine months ended September 30, 2024.

~~Table~~Revenue ofby ~~Contents~~Type


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	7,664	$	5,999
MRI Compatible Patient Vital Signs Monitoring Systems	7,107		6,545
Ferro Magnetic Detection Systems	621		418
Total devices revenue	15,392		12,962
Amortization of extended maintenance agreements	659		560
Disposables	4,885		4,947
Services and other	1,043		1,042
Total revenue	$	21,979	$	19,511

For the three months ended March 31, 2026, total revenue increased by $2.5 million, or 13%, to $22.0 million from $19.5 million for the same period in 2025. This increase is primarily attributed to continued demand for our IV infusion pump systems, amortization of extended maintenance revenue, and modifications to our sales incentive plan for patient vital signs monitoring systems.

Revenue from sales in the U.S. increased by $2.1 million, or 13%, to $18.0 million for the three months ended March 31, 2026, from $16.0 million for the same period in 2025. Revenue from sales internationally increased for the three months ended March 31, 2026 and 2025 at $4.0 million. Domestic sales accounted for 82% of revenue for the three months ended March 31, 2026 and 2025.

Revenue from sales of devices increased by $2.4 million, or 19%, to $15.4 million for the three months ended March 31, 2026, from $13.0 million for the same period in 2025. Revenue from the amortization of extended maintenance agreements increased by $99 thousand, or 18%, to $659 thousand for the three months ended March 31, 2026, from $560 thousand for the three months ended March 31, 2025. Revenue from sales of disposables remained constant at $4.9 million for the three months ended March 31, 2026 and 2025. Revenue from services and other remained constant at $1.0 million for the three months ended March 31, 2026 and 2025.

Cost of Revenue and Gross Profit


	Three Months Ended March 31,
	2026			2025
(in thousands)	(unaudited)
Revenue	$	21,979		$	19,511
Cost of revenue	5,165			4,668
Gross profit	$	16,814		$	14,843
Gross profit percentage	77		%	76		%


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
	(unaudited)						(unaudited)
Revenue	$	21,202,064		$	18,325,959		$	61,122,101		$	53,852,954
Cost of revenue		4,707,756			4,134,253			13,829,995			12,263,932
Gross profit	$	16,494,308		$	14,191,706		$	47,292,106		$	41,589,022
Gross profit percentage		78	%		77	%		77	%		77	%

For the three months ended March 31, 2026, our cost of revenue increased by $0.5 million, or 11%, to $5.2 million from $4.7 million for the same period in 2025. For the three months ended March 31, 2026, our gross profit increased by $2.0 million, or 13%, to $16.8 million from $14.8 million for the same period in 2025. For the three months ended March 31, 2026, gross profit margin increased to 77% compared to 76% for the same period in 2025.

For the three months ended September 30, 2025, our cost of revenue increased by $0.6 million, or 14%, to $4.7 million from $4.1 million for the same period in 2024. For the three months ended September 30, 2025, our gross profit increased by $2.3 million, or 16%, to $16.5 million from $14.2 million for the same period in 2024. For the three months ended September 30, 2025, gross profit margin increased to 78% compared to 77% for the same period in 2024.

For the nine months ended September 30, 2025, our cost of revenue increased by $1.5 million, or 13%, to $13.8 million from $12.3 million for the same period in 2024. For the nine months ended September 30, 2025, our gross profit increased by $5.7 million, or 14%, to $47.3 million from $41.6 million for the same period in 2024. Gross profit margin remained at 77% for both the nine months ended September 30, 2025 and 2024.

Operating Expenses


		Three Months EndedMarch 31,
	Three Months Ended						Nine Months Ended
		2026					2025
	September 30,						September 30,
(in thousands)		(unaudited)
	2025			2024			2025			2024
General and administrative		$	4,569				$	4,611
	(unaudited)						(unaudited)
Percentage of revenue		20.8		%			23.6		%
General and administrative	$	4,355,636		$	3,967,799		$	13,246,461		$	12,063,971
Sales and marketing		$	4,052				$	4,176
Percentage of revenue		2018.64	%	%	~~21.7~~	%	21.4	~~21.7~~	%		~~22.4~~	%
Sales and marketing	$	4,630,560		$	3,795,320		$	12,816,473		$	11,098,945
Research and development		$	957				$	624
Percentage of revenue		214.84	%	%	~~20.7~~	%	3.2	~~21.0~~	%		~~20.6~~	%
Research and development	$	674,362		$	639,467		$	2,175,969		$	2,261,596
Percentage of revenue		3.2	%		3.5	%		3.6	%		4.2	%

General and Administrative

For the three months ended ~~September 30~~March 31, ~~2025~~ 2026 , general and administrative expense ~~increased~~remained byconsistent ~~$0.4~~at ~~million, or 10%, to~~ $4.46 million ~~from $4~~.0 ~~million for the same period in 2024. This increase is primarily due to higher legal and professional expenses, software maintenance, and increased payroll and benefit expenses.~~

For the nine months ended September 30, 2025, general and administrative expense increased by $1.1 million, or 9%, to $13.2 million from $12.1 million for the same period last year. This increase is primarily due to higher legal and professional expenses, regulatory consulting, and payroll and benefits expenses.

Sales and Marketing

For the three months ended ~~September 30~~March 31, ~~2025~~ 2026, sales and marketing expense ~~increased~~decreased by $0.81 million, or 213%, to $4.61 million from $34.82 million for the same period in ~~2024~~2025. This increase is primarily due to ~~higher~~reduced sales commissions, ~~sales~~related ~~activities~~to ~~expenses,~~timing and ~~payroll~~transition ~~and~~of ~~benefits~~sales ~~expenses~~focus to our MRidium® 3870 IV infusion pump system.

For the nine months ended September 30, 2025, sales and marketing expense increased by $1.7 million, or 15%, to $12.8 million from $11.1 million for the same period last year. This increase is primarily due to higher sales commissions, sales activities expenses, and payroll and benefits expense.

Table of Contents

Research and Development

For the three months ended ~~September 30~~March 31, ~~2025~~ 2026, research and development expense increased by $350.4 ~~thousand~~million, or 567%, to $~~674~~1.0 ~~thousand~~million from $~~639~~0.6 ~~thousand~~million for the same period in ~~2024~~2025. This increase is primarily due to an increase in payroll and benefit expenses. Payroll expenses related to the ~~newly cleared~~ MRidium® 3870 IV infusion pump system, were capitalized for the same period in 2025.

For the nine months ended September 30, 2025, research and development expense decreased $0.1 million, or 4%, to $2.2 million from $2.3 million for the same period last year. This decrease is primarily due to decreased prototype and consulting expenses related to the MRidium® 3870 IV infusion pump system.

Other Income, Net

Other income, net consists of interest income, (the largest component), foreign currency gains and losses, and other miscellaneous income. For the three months ended ~~September 30~~March 31, ~~2025~~ 2026, other income, net ~~decreased~~increased $~~165~~19 thousand, or 264%, to $~~464~~532 thousand from $~~629~~513 thousand for the same period in ~~2024~~2025.

For the nine months ended September 30, 2025 and 2024, other income, net decreased $0.3 million, or 14%, to $1.5 million from $1.8 million for the same period in 2024. This income is primarily interest received in 2025 and 2024 on money market fund investments.

Income Taxes

OnWe ~~July~~file ~~31,~~tax ~~2024,~~returns ~~the~~in ~~Company received a notice of examination from~~ the IU.R.S. ~~for~~federal ~~the~~jurisdiction ~~tax~~and ~~year~~many ~~ended December 31, 2021~~U.S. Onstate ~~July 29, 2025, the Company received notice that the I~~jurisdictions.~~R.S.~~ ~~completed~~Our ~~its~~returns ~~review~~are ofnot ~~our~~currently ~~tax~~under ~~return~~examination ~~for~~by the ~~tax~~Internal ~~year~~Revenue ~~ended December 31, 2021, with no changes to our reported tax return and closed out its examination~~Service. The Company remains subject to income tax examinations for our U.S. federal and certain U.S. state income taxes for ~~2022~~2023 and subsequent years.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA includes several significant provisions, including the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions, such as accelerated deductions for qualified property and domestic research expenditures. The

Company has evaluated the impact of the OBBBA on its financial statements and does not expect the legislation to result in a material change to its annual effective tax rate. During the first quarter of 2026, the Company implemented the OBBBA‑related changes to the foreign‑derived deduction regime, including the transition from the FDII deduction to the FDDEI deduction, which became effective for tax years beginning after December 31, 2025.

Liquidity and Capital Resources

Our principal sources of liquidity have historically been our cash and cash equivalents balances, cash flow from operations and access to the financial markets. Our principal uses of cash are operating expenses, working capital requirements, capital expenditures and dividend payments.

As of ~~September~~March 3031, ~~2025~~ 2026, we had cash and cash equivalents of $56.54 million, stockholders’ equity of $98.45 million, and working capital of $7274.13 million. As of December 31, ~~2024~~ 2025, we had cash and cash equivalents of $5251.2 million, stockholders’ equity of $8694.86 million, and working capital of $6671.70 million.

OnWe ~~April~~believe 3,that ~~2024~~our current cash, ~~the~~and ~~Company~~cash ~~filed~~generated afrom ~~shelf~~operations ~~registration~~will ~~statement~~be onsufficient ~~Form~~to ~~S-3~~meet (our ongoing operating requirements for at least the ~~“2024~~next ~~Shelf”)~~12 months and into the foreseeable future. We do not anticipate requiring additional capital; however, ~~which~~if ~~was~~required ~~declared~~or ~~effective~~desirable, bywe ~~the~~may ~~SEC~~seek onto ~~May~~obtain 8a credit facility, ~~2024~~raise debt, or issue additional equity in private or public markets. ~~The~~Various ~~2024~~economic ~~Shelf~~conditions ~~covers~~(including ~~the~~persistent ~~offering~~inflationary pressures, ~~issuance~~elevated ~~and~~or ~~sale~~volatile byinterest rate levels, and the ~~Company~~imposition of, upexpansion toof, anor ~~aggregate~~changes ofin ~~$75.0~~tariffs ~~million~~or ofother ~~its~~trade ~~common~~restrictions) ~~stock.~~may Asdisrupt ofcapital ~~September 30~~markets at any time, ~~2025,~~ ~~all~~which ~~$75.0~~could ~~million~~reduce ~~remained~~our ~~available~~ability ~~under~~to ~~the~~access ~~2024~~capital ~~Shelf~~and negatively affect our liquidity in the future.


	Three Months Ended March 31,
	2026		2025
(in thousands)	(unaudited)
Net cash provided by operating activities	$	8,290	$	4,292
Net cash used in investing activities	(469)		(3,917)
Net cash used in financing activities	(2,606)		(2,278)

~~Table~~Cash ofprovided ~~Contents~~by operating activities increased by $4.0 million, to $8.3 million for the three months ended March 31, 2026, compared to $4.3 million for the same period in 2025. During the three months ended March 31, 2026, cash provided by operations was positively impacted by higher net income, and lower cash outflows related to accounts payable, pre-paid expenses, and inventory purchases, and offset by an increase in accounts receivable related to timing.

WeCash ~~believe~~used ~~that~~in ~~our~~investing ~~current~~activities ~~cash,~~decreased ~~and~~by ~~any~~$3.4 ~~cash~~million, ~~generated from operations will be sufficient~~ to ~~meet~~$0.5 ~~our~~million ~~ongoing operating requirements~~ for ~~at least~~ the ~~next~~three 12 months ~~and~~ended ~~into~~March ~~the foreseeable future. We do not anticipate requiring additional capital; however~~31, ~~if required or desirable~~2026, wecompared ~~may seek~~ to ~~obtain~~$3.9 amillion ~~credit~~for ~~facility,~~the ~~raise~~same ~~debt,~~period ~~or issue additional equity~~ in ~~private~~2025. orThe ~~public~~decrease ~~markets.~~from ~~Various~~our ~~economic~~2025 ~~conditions~~spend ~~might~~in ~~disrupt~~investing ~~capital~~activities ~~markets~~is atattributed ~~any~~to ~~time,~~construction ~~which~~costs ~~could~~of ~~reduce~~the ~~our~~completed ~~ability~~new toexecutive ~~access~~offices ~~capital~~ and ~~negatively~~expanded ~~affect~~manufacturing ~~our~~facility ~~liquidity~~to inaccommodate ~~the~~our ~~future~~continued growth.

Cash used in financing activities increased by $0.3 million, to $2.6 million for the three months ended March 31, 2026, compared to approximately $2.3 million for the same period in 2025. The increase is primarily due to the per share increase of a regular quarterly cash dividend payment. Special and quarterly cash dividend payments are subject to the sole discretion of the Board and applicable law.


	Nine Months Ended
	September 30,
	2025		2024
	(unaudited)
Net cash provided by operating activities	$	19,024,428	$	19,637,394
Net cash used in investing activities		(8,004,593)		(5,760,057)
Net cash used in financing activities		(6,727,591)		(11,918,484)

Cash provided by operating activities decreased by $0.6 million, to $19.0 million for the nine months ended September 30, 2025, compared to $19.6 million for the same period in 2024. During the nine months ended September 30, 2025, cash provided by operations was positively impacted by higher net income, lower cash outflows related to accounts payable, and negatively impacted by increased inventory purchases, prepaid expenses and accounts receivable.

Cash used in investing activities increased by $2.2 million, to $8.0 million for the nine months ended September 30, 2025, compared to $5.8 million for the same period in 2024. The majority of our 2025 spend in investing activities is attributed to construction costs of the completed New Facility to accommodate our anticipated growth.

Cash used in financing activities decreased by $5.2 million, to $6.7 million for the nine months ended September 30, 2025, compared to approximately $11.9 million for the same period in 2024. The decrease is primarily due to December 2023 declaration of a special cash dividend and subsequent payment in the first quarter of 2024. In the second quarter of 2024, the Company commenced paying a regular quarterly cash dividend payment. Special and quarterly cash dividend payments are subject to the sole discretion of the Board and applicable law.

We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses.

Off-Balance Sheet Arrangements

As of ~~September~~March 3031, ~~2025~~ 2026 and December 31, ~~2024~~ 2025, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

There have been no material changes outside the ordinary course of business to our contractual obligations and commercial commitments since December 31, ~~2024~~ 2025.

Recent Accounting Pronouncements

As of ~~September~~March 3031, ~~2025~~ 2026, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the ~~2024~~2025 Annual Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes in our market risks from those disclosed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of the ~~2024~~2025 Annual Report.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that: (1) information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (2) such information is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of ~~September~~March 3031, ~~2025~~ 2026. Our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of ~~September~~March 3031, ~~2025~~ 2026 were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. We do not believe that any such known matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, results of operations or cash flows.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report, you should carefully consider the risks discussed in our ~~2024~~2025 Annual Report and those set forth from time to time in our other filings with the SEC. There have been no material changes in our risk factors from those described in our ~~2024~~2025 Annual Report ~~and in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025~~. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, or future results.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

None.

Item 3. Default Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information

Rule 10b5-1 Trading Arrangement Changes

None of the Company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarterly period ended March 31, 2026.

None of the Company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarterly period ended September 30, 2025.

Table of Contents

Item 6. Exhibits

ExhibitNumber	~~Description of Document~~	Description of Document
31.1	~~Certification of Chief Executive Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~	Certification of Chief Executive Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	~~Certification of Chief Financial Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.~~	Certification of Chief Financial Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	~~Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.~~	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	~~Inline XBRL Instance Document~~	Inline XBRL Instance Document
101.SCH	~~XBRL Taxonomy Extension Schema Document~~	XBRL Taxonomy Extension Schema Document
101.CAL	~~XBRL Taxonomy Extension Calculation Linkbase Document~~	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	~~XBRL Taxonomy Extension Definition Linkbase Document~~	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	~~XBRL Taxonomy Extension Label Linkbase Document~~	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	~~XBRL Taxonomy Extension Presentation Linkbase Document~~	XBRL Taxonomy Extension Presentation Linkbase Document
104	~~Inline XBRL for the cover page of this Quarterly Report , included as part of this Exhibit 101 inline XBRL Document set~~	Inline XBRL for the cover page of this Quarterly Report , included as part of this Exhibit 101 inline XBRL Document set

* This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.________________________________________________________

*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

Table of Contents

IRADIMED CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	IRADIMED CORPORATION

Dated: May 1, 2026	/s/ Roger Susi
	By:	Roger Susi
	Its:	Chief Executive Officer and President (Principal Executive Officer and Authorized Officer)

	/s/ John Glenn
	By:	John Glenn
	Its:	Chief Financial Officer (Principal Financial and Accounting Officer)

	IRADIMED CORPORATION
Dated: November 3, 2025	/s/ Roger Susi
	By:	Roger Susi
	Its:	Chief Executive Officer and President
		(Principal Executive Officer and Authorized Officer)

	/s/ John Glenn
	By:	John Glenn
	Its:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

Filing Compare · IRADIMED CORP